Log in

NYSE:AMRXAmneal Pharmaceuticals Stock Price, Forecast & News

$4.52
-0.12 (-2.59 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$4.50
Now: $4.52
$4.73
50-Day Range
$4.12
MA: $4.71
$5.11
52-Week Range
$2.27
Now: $4.52
$7.28
Volume961,090 shs
Average Volume1.51 million shs
Market Capitalization$1.35 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.52
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections. It also offers licensed and owned, niche, and mature branded products, as well as Rytary for the treatment of Parkinsons Disease; Zomig for the treatment of migraine headaches; Emverm a chewable tablets for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; and Unithroid for the treatment of hypothyroidism. The company has operations in the United States, Switzerland, India, Ireland, the United Kingdom and internationally. Amneal Pharmaceuticals, Inc. was founded in 2002 and is based in Bridgewater, New Jersey.
Read More
Amneal Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.1Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 2.5 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.96 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone908-947-3120

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.63 billion
Cash Flow$1.12 per share
Book Value$1.16 per share

Profitability

Net Income$-361,920,000.00

Miscellaneous

Employees5,500
Market Cap$1.35 billion
Next Earnings Date8/3/2020 (Estimated)
OptionableOptionable

Receive AMRX News and Ratings via Email

Sign-up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter.

Amneal Pharmaceuticals (NYSE:AMRX) Frequently Asked Questions

How has Amneal Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Amneal Pharmaceuticals' stock was trading at $3.25 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, AMRX stock has increased by 39.1% and is now trading at $4.52. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Amneal Pharmaceuticals?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last year. There are currently 1 sell rating, 7 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Amneal Pharmaceuticals.

When is Amneal Pharmaceuticals' next earnings date?

Amneal Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Amneal Pharmaceuticals.

How were Amneal Pharmaceuticals' earnings last quarter?

Amneal Pharmaceuticals Inc (NYSE:AMRX) posted its quarterly earnings results on Monday, May, 11th. The company reported $0.20 earnings per share for the quarter, beating analysts' consensus estimates of $0.09 by $0.11. The company earned $498.50 million during the quarter, compared to analyst estimates of $446.12 million. Amneal Pharmaceuticals had a positive return on equity of 22.05% and a negative net margin of 11.85%. The business's quarterly revenue was up 12.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.14 EPS. View Amneal Pharmaceuticals' earnings history.

What guidance has Amneal Pharmaceuticals issued on next quarter's earnings?

Amneal Pharmaceuticals updated its FY20 earnings guidance on Monday, May, 11th. The company provided earnings per share (EPS) guidance of $0.45-0.60 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.50. The company issued revenue guidance of $1.88-1.98 billion, compared to the consensus revenue estimate of $1.87 billion.

What price target have analysts set for AMRX?

11 analysts have issued 1-year price targets for Amneal Pharmaceuticals' stock. Their forecasts range from $2.50 to $8.50. On average, they anticipate Amneal Pharmaceuticals' share price to reach $5.10 in the next twelve months. This suggests a possible upside of 12.8% from the stock's current price. View analysts' price targets for Amneal Pharmaceuticals.

Has Amneal Pharmaceuticals been receiving favorable news coverage?

Media coverage about AMRX stock has trended negative recently, InfoTrie reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Amneal Pharmaceuticals earned a news impact score of -2.1 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about Amneal Pharmaceuticals.

Are investors shorting Amneal Pharmaceuticals?

Amneal Pharmaceuticals saw a drop in short interest during the month of June. As of June 15th, there was short interest totaling 6,090,000 shares, a drop of 9.2% from the May 31st total of 6,710,000 shares. Based on an average trading volume of 2,190,000 shares, the days-to-cover ratio is currently 2.8 days. Approximately 6.5% of the shares of the company are short sold. View Amneal Pharmaceuticals' Current Options Chain.

Who are some of Amneal Pharmaceuticals' key competitors?

What other stocks do shareholders of Amneal Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amneal Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Canopy Growth (CGC), Exelixis (EXEL), Intelsat (I), Micron Technology (MU), Nektar Therapeutics (NKTR), Teva Pharmaceutical Industries (TEVA), AbbVie (ABBV), Amarin (AMRN) and Alibaba Group (BABA).

Who are Amneal Pharmaceuticals' key executives?

Amneal Pharmaceuticals' management team includes the following people:
  • Mr. Paul M. Bisaro, Exec. Chairman (Age 58)
  • Mr. Chirag K. Patel, Co-Founder & Co-Chairman (Age 52)
  • Mr. Chintu Patel, Co-Founder & Co-Chairman (Age 47)
  • Mr. Robert A. Stewart, Pres, CEO & Director (Age 51)
  • Ms. Nikita Shah, Sr. VP & Chief HR Officer (Age 41)

What is Amneal Pharmaceuticals' stock symbol?

Amneal Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "AMRX."

How do I buy shares of Amneal Pharmaceuticals?

Shares of AMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Amneal Pharmaceuticals' stock price today?

One share of AMRX stock can currently be purchased for approximately $4.52.

How big of a company is Amneal Pharmaceuticals?

Amneal Pharmaceuticals has a market capitalization of $1.35 billion and generates $1.63 billion in revenue each year. The company earns $-361,920,000.00 in net income (profit) each year or $0.27 on an earnings per share basis. Amneal Pharmaceuticals employs 5,500 workers across the globe.

What is Amneal Pharmaceuticals' official website?

The official website for Amneal Pharmaceuticals is www.amneal.com.

How can I contact Amneal Pharmaceuticals?

Amneal Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The company can be reached via phone at 908-947-3120 or via email at [email protected]

This page was last updated on 7/6/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.